CTLA4 and melanoma: In 2011, the U.S. Food and Drug Administration approved ipilimumab, an anti-CTLA-4 antibody, for melanoma to increase the mobility of T cells and allow the cytotoxic T cells to continue to destroy cancer cells [9,10,11,12].